

c.13dup — WFS1 Molecular Atlas Card

Variant type: Frameshift

Frameshift point: residue 5

Predicted premature stop (PTC): residue 55

Domain context (where the frame breaks): N-terminal cytoplasmic (intrinsically disordered)

SCHEMA CATEGORY: F1 — FRAMESHIFT, NMD-TARGETED — NULL ALLELE

The frameshift creates a premature termination codon well upstream of the last exon-exon junction; the 50-nt rule predicts the transcript is degraded by nonsense-mediated decay. No frameshifted protein is produced — functionally a null allele. Therapeutic options: (a) translational readthrough drugs (Ataluren/PTC124, aminoglycosides) — notably LESS effective for frameshifts than for nonsense variants, because reading through the PTC still yields out-of-frame protein; (b) gene therapy via allele replacement is the higher-yield path.

PREMATURE-STOP PREDICTION

- **Frameshift point:** aa 5
- **Predicted PTC:** aa 55 (50 codons downstream of the frame break)
- **Method:** deterministic translation of edited NM_006005.3 CDS (frameshift position = first changed residue, HGVS convention)
- **Confidence:** high

NMD PREDICTION

- **Status:** NMD-targeted
- **Confidence:** high
- **Reasoning:** Stop codon at position 55 is more than 50 nt upstream of the last exon-exon junction (~aa 413). The 50-nt rule predicts the transcript is degraded by nonsense-mediated

decay. No truncated protein is produced; functionally a null allele.

PROTEIN CONSEQUENCE

- **Native (wild-type) sequence retained:** aa 1 – 4 (0.4% of full-length protein)
- **Non-native scrambled stretch:** aa 5 – 54 (50 residues of out-of-frame sequence)
- **Lost beyond the PTC:** aa 55 – 890 (836 residues)

Native domains retained (upstream of the frameshift)

(no domains fully retained)

Domain interrupted at the frameshift point

- **N-terminal cytoplasmic (intrinsically disordered)** — native aa 1–4 retained; aa 5–310 replaced by non-native sequence

Native domains downstream of the frameshift (lost or non-native)

- Transmembrane helix 1 (aa 311–331)
 - Cytoplasmic loop 1 (aa 332–340)
 - Transmembrane helix 2 (aa 341–361)
 - Luminal loop 1 (aa 362–370)
 - Transmembrane helix 3 (aa 371–391)
 - Cytoplasmic loop 2 (aa 392–400)
 - Transmembrane helix 4 (aa 401–421)
 - Luminal loop 2 (aa 422–431)
 - Transmembrane helix 5 (aa 432–452)
 - Cytoplasmic loop 3 (aa 453–461)
 - Transmembrane helix 6 (aa 462–482)
 - Luminal loop 3 (aa 483–496)
 - Transmembrane helix 7 (aa 497–517)
 - Cytoplasmic loop 4 (aa 518–532)
 - Transmembrane helix 8 (aa 533–553)
 - Luminal loop 4 (aa 554–573)
 - Transmembrane helix 9 (aa 574–594)
 - Cytoplasmic loop 5 / pre-luminal (aa 595–599)
 - C-terminal ER-luminal (calcium binding, calmodulin, chaperone) (aa 600–890)
-

CLINICAL EVIDENCE

- **Classification:** Pathogenic
 - **Review status:** criteria provided, single submitter
 - **cDNA change:** c.13dup
 - **ClinVar accession:** VCV002044055
 - **Last evaluated:** 2023/07/21 00:00
 - **Submissions:** 1
-

WHY THIS VARIANT MATTERS

The frame breaks early enough that the premature stop is caught by nonsense-mediated decay — the transcript is degraded before any out-of-frame protein accumulates. That makes this, in effect, a clean null allele: the atlas points the therapeutic conversation at gene replacement, and notes that readthrough drugs are a weaker fit here than for true nonsense variants because reading through the stop still yields scrambled protein.

Card generated by `wolfram-atlas-batch` skill (v2 — frameshift pipeline) on 2026-06-08T02:15:25.420375Z.

NMD rule and schema definitions: `reference/nmd` rules.md , `reference/cardschemaextension`.md .__

CDS reference: NM006005.3 (171..2843). WFS1 reference: UniProt O76024, AlphaFold model v6.__